SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Assets
Total assets	$ 139,382	$ 370,936
Liabilities
Total liabilities	3,244,238	3,667,911
Stockholders’ equity
Preferred stock, $0.001 par value
Common stock, $0.001 par value	144,642	123,346
Additional paid-in capital	13,085,715	8,397,109
Non-controlling interest	(680,886)	(590,628)
Accumulated deficit	(15,699,327)	(11,226,802)
Total stockholders’ deficit	(3,104,856)	(3,296,975)	$ (3,158,207)
Total liabilities and stockholders’ equity	139,382	370,936
Loss from operations	(3,800,212)	(2,436,541)
Adjustment to other income		300,000
Loss of issuance	(212,458)
Total other expenses	(762,571)	(229,965)
Net loss	(4,562,783)	(2,666,506)
Net loss attributable to the non-controlling interest	90,258	193,372
NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$ (4,472,525)	$ (2,473,134)
Loss per Common share, basic	$ (0.03)	$ (0.02)
Loss per Common share, diluted	$ (0.03)	$ (0.02)
Adjustment of average number of Common shares out-standing	(2,427,075)	(251,473)
Weighted average number of Common shares outstanding, basic	133,973,352	112,712,305
Weighted average number of Common shares outstanding, diluted	133,973,352	112,712,305
Weighted average number of Common shares outstanding, basic	(133,973,352)	(112,712,305)
Weighted average number of Common shares outstanding, diluted	(133,973,352)	(112,712,305)
Net loss	$ (4,562,783)	$ (2,666,506)
Net cash used in operating activities	(775,375)	(1,803,670)
Net cash used in investing activities	(44,301)	(32,247)
Net cash provided by financing activities	550,361	2,058,960
Net change in cash	(269,315)	223,043
Previously Reported [Member]
Assets
Adjustment to Intangibles
Total assets	137,638	370,936
Liabilities
Total liabilities	3,249,500	3,663,482
Stockholders’ equity
Preferred stock, $0.001 par value
Common stock, $0.001 par value	145,642	123,252
Additional paid-in capital	12,920,984	8,392,430
Non-controlling interest	(680,886)	(590,628)
Accumulated deficit	(15,497,602)	(11,217,600)
Total stockholders’ deficit	(3,111,862)	(3,292,546)
Total liabilities and stockholders’ equity	137,638	370,936
Loss from operations	(3,820,147)	(2,134,112)
Adjustment to other income
Loss of issuance
Total other expenses	(550,113)	(523,192)
Net loss	(4,370,260)	(2,657,304)
Net loss attributable to the non-controlling interest	90,258	193,372
NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$ (4,280,002)	$ (2,463,932)
Loss per Common share, basic	$ (0.03)	$ (0.02)
Loss per Common share, diluted	$ (0.03)	$ (0.02)
Weighted average number of Common shares outstanding, basic	134,224,825	115,139,380
Weighted average number of Common shares outstanding, diluted	134,224,825	115,139,380
Weighted average number of Common shares outstanding, basic	(134,224,825)	(115,139,380)
Weighted average number of Common shares outstanding, diluted	(134,224,825)	(115,139,380)
Net loss	$ (4,370,260)	$ (2,657,304)
Adjustment to reconcile net loss to net cash used in operating activities
Net cash used in operating activities	(775,375)	(1,805,670)
Net cash used in investing activities	(44,301)	(32,247)
Net cash provided by financing activities	550,361	2,060,960
Net change in cash	(269,315)	223,043
Revision of Prior Period, Adjustment [Member]
Assets
Adjustment to Intangibles	1,744
Total assets	1,744
Liabilities
Adjustments to accounts payable	(6,369)	4,429
Adjustments to unissued shares	11,631
Total liabilities	(5,262)	4,429
Stockholders’ equity
Preferred stock, $0.001 par value
Adjustment to Common Stock	(1,000)	94
Common stock, $0.001 par value	(1,000)	94
Adjustment to APIC	164,731	4,679
Additional paid-in capital	164,731	4,679
Non-controlling interest
Accumulated deficit	(201,725)	(9,202)
Total stockholders’ deficit	7,006	(4,429)
Total liabilities and stockholders’ equity	1,744
Adjustment to R&D		(300,000)
Adjustment to GNA	19,935	(9,202)
Loss from operations	19,935	(309,202)
Adjustment to other income		300,000
Loss of issuance	(212,458)
Total other expenses	(212,458)	300,000
Net loss	(192,523)	(9,202)
Net loss attributable to the non-controlling interest
NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$ (192,523)	$ (9,202)
Loss per Common share, basic
Loss per Common share, diluted
Adjustment of average number of Common shares out-standing	(251,473)	(2,427,075)
Weighted average number of Common shares outstanding, basic	251,473	2,427,075
Weighted average number of Common shares outstanding, diluted	251,473	2,427,075
Weighted average number of Common shares outstanding, basic	(251,473)	(2,427,075)
Weighted average number of Common shares outstanding, diluted	(251,473)	(2,427,075)
Net loss	$ (192,523)	$ (9,202)
Adjustment to reconcile net loss to net cash used in operating activities	192,523	7,202
Net cash used in operating activities		2,000
Net cash used in investing activities
Adjustment in cash investment		(2,000)
Net cash provided by financing activities		(2,000)
Net change in cash
As Restated [Member]
Assets
Adjustment to Intangibles	1,744
Total assets	139,382	370,936
Liabilities
Adjustments to accounts payable	(6,369)	4,429
Adjustments to unissued shares	11,631
Total liabilities	3,244,238	3,667,911
Stockholders’ equity
Preferred stock, $0.001 par value
Adjustment to Common Stock	(1,000)	94
Common stock, $0.001 par value	144,642	123,346
Adjustment to APIC	164,731	4,679
Additional paid-in capital	13,085,715	8,397,109
Non-controlling interest	(680,886)	(590,628)
Accumulated deficit	(15,699,327)	(11,226,802)
Total stockholders’ deficit	(3,104,856)	(3,296,975)
Total liabilities and stockholders’ equity	139,382	370,936
Adjustment to R&D		(300,000)
Adjustment to GNA	19,935	(9,202)
Loss from operations	(3,800,212)	(2,436,541)
Adjustment to other income		300,000
Loss of issuance	(212,458)
Total other expenses	(762,571)	(229,965)
Net loss	(4,562,783)	(2,666,506)
Net loss attributable to the non-controlling interest	90,258	193,372
NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$ (4,472,525)	$ (2,473,134)
Adjustment of average number of Common shares out-standing	(251,473)	(2,427,075)
Net loss	$ (4,562,783)	$ (2,666,506)
Adjustment to reconcile net loss to net cash used in operating activities	192,523	7,202
Net cash used in operating activities	(775,375)	(1,803,670)
Net cash used in investing activities	(44,301)	(32,247)
Adjustment in cash investment		(2,000)
Net cash provided by financing activities	550,361	2,058,960
Net change in cash	$ (269,315)	$ 223,043